Drugs /

plicamycin

Back to Drugs List

Overview

NCI Definition [1]:
An antibiotic isolated from the bacterium Streptomyces plicatus with antineoplastic activity. Plicamycin, also known as mithramycin, binds to the minor groove of DNA at GC-rich sites, resulting in inhibition of RNA synthesis; this agent also inhibits mRNA expression, resulting in a reduction in protein synthesis. In addition, plicamycin may inhibit bone resorption by down regulating transcription of c-src, an oncogene involved in bone metabolism and resorption. (NCI04

Clinical Trials

View Clinical Trials for plicamycin

Plicamycin has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating plicamycin, 1 is phase 2 (0 open).

Colorectal carcinoma, esophageal carcinoma, and gastric carcinoma are the most common diseases being investigated in plicamycin clinical trials [2].

Drug Details

Synonyms [2]:
mithramycin
NCIT ID [1]:
C658

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.